The European approval for the Vitalis implant family includes the ReSyncra CSP, Restoria CSP, Refina CSP, Effectra and Confirma pacemakers designed to address a wide variety of patients.
ReSyncra CSP, for example, carries additional technology aimed at people who may benefit from cardiac resynchronization therapy, or CRT, but have not seen success with traditional approaches that aim to restore the proper timing of beats between the heart’s left and right ventricles.